Mathematics against resistances
Resistance to chemotherapy is a major cause of cancer treatment failure. The acquisition of resistance in cancer is a complex phenomenon that could be driven by tumor heterogeneity and genetic and epigenetic changes. Key processes involved in resistance development during systemic cancer therapy are evolutionary adaptation to therapy, Lamarckian development of resistance induced by treatment and the transfer of resistance factors. These processes can be described through mathematical models that can help in finding optimal ways of treating the tumors deferring or eliminating resistance development.
Publications
-
On optimal temozolomide scheduling for slowly growing glioblastomasB. Segura-Collar, J. Jiménez-Sánchez, R. Gargini, M. Dragoj, J. M. Sepúlveda, M. Pesic, M. A. Ramírez, L. E. Ayala-Hernández, P.Sánchez-Gómez, V. M Pérez-GarcíaNeuro-Oncology Advances 4(1), vdac155, 1-13 (2022)
-
In vitro biomimetic models for glioblastoma-a promising tool for drug response studiesT. Stankovic, T. Randelovic, M. Dragoj, S.S. Buric, L. Fernández, I. Ochoa, V.M. Pérez-García, M. PesicDrug Resistance Updates 55, 100753 (2021)
-
Identification of a transient state during the acquisition of temozolomide resistance in glioblastomaM. Rabe, S. Dummont, A. Álvarez-Arenas Alcami, H. Janati, J. Belmonte-Beitia, G.F. Calvo, C. Thibault-Charpentier, Q. Séry, C. Chauvin, N. Joalland, F. Briand, E. Scotet, C. Pecqueur, J. Clairambault, L. Oliver, A. Nadaradjane, V.M. Pérez-García, P. François Cartron, C. Gratas, F.M. ValletteCell Death & Disease 11, 19 (2020)
-
Mitochondria transfer from tumor-activated stromal cells (TASCs) to primary Glioblastoma cells.C. Salaud, A. Alvarez-Arenas Alcami, F. Geraldo, J. Belmonte-Beitia, G.F. Calvo, C. Gratas, C. Pecqueur, D. Garnier, V.M. Pérez- García, F.M. Vallette, L. OliverBiochemical and Biophysical Research Communications 533(1) 139-147 (2020)
-
Computational design of improved standardized chemotherapy protocols for grade II oligodendrogliomas.V.M. Pérez-García, L.E. Ayala-Hernández, J. Belmonte-Beitia, P. Schucht, M. Murek, A. RaabePLOS Computational Biology 15(7) (2019) e1006778
-
Interplay of Darwinian Selection, Lamarckian Induction and Microvesicle Transfer on Drug Resistance in Cancer.A. Alvarez-Arenas, A. Podolski-Renic, J. Belmonte-Beitia, M. Pesic, G.F. CalvoScientific Reports 9:9332 (2019)
-
Modulation of antioxidant potential with coenzyme Q10 suppressed invasion of temozolomide resistant rat glioma in vitro and in vivoS. Stojkovic, A. Podolski-Renic, J. Dinic, T. Stankovic, M. Jovanovic, S. Hadžic, J.M. Ayuso, M. Virumbrales-Muñoz, L.J. Fernández, I. Ochoa, V.M. Perez-Garcia, M. PešicOxidative Medicine and Cellular Longevity 2019, 3061607 (2019)
-
Ultimate dynamics and optimal control of a multi-compartment model of tumor resistance to chemotherapyA. Alvarez-Arenas, K.E. Starkov, G.F. Calvo, J. Belmonte-BeitiaDiscrete and Continuous Dynamical Systems B 24(5) 2017-2038 (2019)
-
Resistance to DNA damaging agents produced invasive phenotype of rat glioma cells-characterization of a new in vivo modelS. Stojkovic, A. Podolski-Renic, J. Dinic, Z. Pavkovic, J.M. Ayuso, L.J. Fernández, I. Ochoa, V.M. Pérez-García, V. Pešic, M. PesicMolecules 21, 843 (2016)
-
Transfer of drug resistance characteristics between cancer cell subpopulations: A study using simple mathematical models.M. Rosa Durán, A. Podolski-Renic, A. Álvarez-Arenas, J. Dinic, J. Belmonte-Beitia, M. Pesic, V. M. Pérez-GarcíaBulletin of Mathematical Biology 78, 1218-1237 (2016)
Projects
-
Ministerio de Economía y Competitividad (2013 - 2015)
-
Junta de Comunidades de Castilla-La Mancha (2018 - 2021)
Collaborators
Our collaborators in this research topic are Philip Maini and Eamonn Gaffney, from University of Oxford. Milica Pešić (Head of the Department of Neurobiology, Institute for Biological Research “Siniša Stanković”, University of Belgrade, Serbia). François Vallette and Lisa Oliver (Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, University of Nantes, France).
